Kymera Investor Presentation Deck
●
●
●
Healthy volunteer SAD and MAD cohorts demonstrated:
Robust and sustained IRAK4 degradation in blood and skin with single and multiple daily doses
Broad inhibition of ex vivo TLR-mediated cytokine induction
Generally well tolerated
●
●
●
Patient cohort demonstrated:
PK, PD and safety comparable to healthy volunteers
Modest, non-adverse QTcF prolongation spontaneously resolved back to baseline during dosing
Robust IRAK4 degradation in blood and skin associated with systemic anti-inflammatory effect in
HS and AD patients, validating pathway and target relevance in HS and AD
●
Key KT-474 Phase 1 Accomplishments
●
●
Promising clinical activity exceeding benchmark placebo rates and comparing favorably to SOC
biologics in both HS and AD
Sanofi has committed to start Ph2 clinical trials, initially in HS and AD
KYMERA Ⓒ2023 KYMERA THERAPEUTICS, INC.
PAGE 13View entire presentation